Ljung R, van den Berg M, Petrini P, Tengborn L, Scheibel E, Kekomäki R, Effenberger W
Department of Paediatrics, University Hospital, Malmö, Sweden.
Acta Paediatr. 1998 Oct;87(10):1051-4. doi: 10.1080/080352598750031365.
Experience of the Port-A-Cath implantable venous access system in 53 children with severe or moderate haemophilia A or B from seven centres in five countries is reviewed. The cumulative duration of follow-up was 1578 months (median 30 months, range 1-114). Of the devices implanted, 70% (37/53) were used without complications (median follow-up 32 months; range 1-114) and the remaining 30% (16/53) were associated with various types of complication: infection, bacteraemia or septicaemia in 56% (9/16) of cases, i.e. a rate of 0.07 per follow-up year or 0.19 per 1000 patient days, or various technical complications occurring after a median of 32 months (range 4-75) of uncomplicated use in the remaining 44% (7/16). Of the patients with inhibitors, 64% (7/11) manifested complications. Both doctors and parents considered that the Port-A-Cath device can be used with an acceptable frequency and severity of complications, and that it enables regular prophylactic or on-demand home treatment of children with haemophilia to be begun at an early age.
回顾了来自五个国家七个中心的53例中重度甲型或乙型血友病患儿使用植入式静脉输液港(Port-A-Cath)系统的经验。累计随访时间为1578个月(中位数30个月,范围1 - 114个月)。在植入的装置中,70%(37/53)使用时无并发症(中位随访32个月;范围1 - 114个月),其余30%(16/53)出现了各种类型的并发症:56%(9/16)的病例发生感染、菌血症或败血症,即每随访年发生率为0.07或每1000患者日发生率为0.19,其余44%(7/16)在无并发症使用中位32个月(范围4 - 75个月)后出现各种技术并发症。在有抑制物的患者中,64%(7/11)出现了并发症。医生和家长都认为,静脉输液港装置使用时并发症的发生频率和严重程度是可以接受的,并且它能够使血友病患儿在幼年时就开始定期进行预防性或按需家庭治疗。